First, it provides a longitudinal comparison of serum calprotectin and CRP, across three clinically relevant timepoints, in patients with RA treated with distinct targeted therapies (IL-6 receptor inhibitor, TNFα inhibitor, and JAK inhibitor). This evidence concerns the gene CRP and rheumatoid arthritis.